Literature DB >> 33637205

Importance of standardizing renal outcomes in clinical trials: illustration by recent sodium glucose cotransporter 2 inhibitor studies.

Daniël H van Raalte1, Petter Bjornstad2, Hiddo J L Heerspink3, Frederik Persson4, David Z I Cherney5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33637205      PMCID： PMC8923155          DOI： 10.1016/j.kint.2020.12.006

Source DB:  PubMed          Journal:  Kidney Int        ISSN： 0085-2538            Impact factor:   10.612


× No keyword cloud information.
  5 in total

1.  Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial.

Authors:  Ofri Mosenzon; Stephen D Wiviott; Avivit Cahn; Aliza Rozenberg; Ilan Yanuv; Erica L Goodrich; Sabina A Murphy; Hiddo J L Heerspink; Thomas A Zelniker; Jamie P Dwyer; Deepak L Bhatt; Lawrence A Leiter; Darren K McGuire; John P H Wilding; Eri T Kato; Ingrid A M Gause-Nilsson; Martin Fredriksson; Peter A Johansson; Anna Maria Langkilde; Marc S Sabatine; Itamar Raz
Journal:  Lancet Diabetes Endocrinol       Date:  2019-06-10       Impact factor: 32.069

2.  Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes.

Authors:  Christopher P Cannon; Richard Pratley; Samuel Dagogo-Jack; James Mancuso; Susan Huyck; Urszula Masiukiewicz; Bernard Charbonnel; Robert Frederich; Silvina Gallo; Francesco Cosentino; Weichung J Shih; Ira Gantz; Steven G Terra; David Z I Cherney; Darren K McGuire
Journal:  N Engl J Med       Date:  2020-09-23       Impact factor: 176.079

3.  Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.

Authors:  Christoph Wanner; Silvio E Inzucchi; John M Lachin; David Fitchett; Maximilian von Eynatten; Michaela Mattheus; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Bernard Zinman
Journal:  N Engl J Med       Date:  2016-06-14       Impact factor: 91.245

4.  Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials.

Authors:  Vlado Perkovic; Dick de Zeeuw; Kenneth W Mahaffey; Greg Fulcher; Ngozi Erondu; Wayne Shaw; Terrance D Barrett; Michele Weidner-Wells; Hsiaowei Deng; David R Matthews; Bruce Neal
Journal:  Lancet Diabetes Endocrinol       Date:  2018-06-21       Impact factor: 32.069

5.  International consensus definitions of clinical trial outcomes for kidney failure: 2020.

Authors:  Adeera Levin; Rajiv Agarwal; William G Herrington; Hiddo L Heerspink; Johannes F E Mann; Shahnaz Shahinfar; Katherine R Tuttle; Jo-Ann Donner; Vivekanand Jha; Masaomi Nangaku; Dick de Zeeuw; Meg J Jardine; Kenneth W Mahaffey; Aliza M Thompson; Mary Beaucage; Kate Chong; Glenda V Roberts; Duane Sunwold; Hans Vorster; Madeleine Warren; Sandrine Damster; Charu Malik; Vlado Perkovic
Journal:  Kidney Int       Date:  2020-10       Impact factor: 10.612
  5 in total
  3 in total

1.  Heart and Kidney Outcomes With Ertugliflozin in People with Non-albuminuric Diabetic Kidney Disease: A post hoc Analysis from the Randomized VERTIS CV Trial.

Authors:  David Z I Cherney; Samuel Dagogo-Jack; Francesco Cosentino; Richard E Pratley; Robert Frederich; Mario Maldonado; Chih-Chin Liu; Christopher P Cannon
Journal:  Kidney Int Rep       Date:  2022-05-13

Review 2.  Transforming the Care of Patients with Diabetic Kidney Disease.

Authors:  Frank C Brosius; David Cherney; Patrick O Gee; Raymond C Harris; Alan S Kliger; Katherine R Tuttle; Susan E Quaggin
Journal:  Clin J Am Soc Nephrol       Date:  2021-06-08       Impact factor: 10.614

3.  Sodium-glucose cotransporter 2 inhibitors: renal outcomes according to baseline albuminuria.

Authors:  Pierre Delanaye; Karl Martin Wissing; Andre J Scheen
Journal:  Clin Kidney J       Date:  2021-06-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.